fbpx
Image Alt

Spartan Trading

  /  Investment Thesis   /  QUARTERLY IN DEPTH INVESTMENT ANALYSIS – TELOMIR PHARMACEUTICALS, INC (NASDAQ: TELO)
TELOMIR - ORAL STEM CELL THERAPY - NASDAQ TELO

QUARTERLY IN DEPTH INVESTMENT ANALYSIS – TELOMIR PHARMACEUTICALS, INC (NASDAQ: TELO)

Disseminated on behalf of Telomir Pharmaceuticals, Inc.

QUARTERLY IN DEPTH INVESTMENT ANALYSIS

Telomir Pharmaceuticals – $TELO

This communication is not an offer to buy or sell securities nor is it to be construed as personal investment advice. Nothing contained in this communication should be relied upon as a promise or representation as to future performance.

TELOMIR - ORAL STEM CELL THERAPY - NASDAQ TELO

For this Quarters In Depth Investment Analysis I am going to be covering a name in one of my favorite sectors to trade – Biotech.

I have been conducting due diligence on this name for the past several months, meeting with the management team and medical advisors to get a better understanding of the novel small molecule they have developed and its future potential implications across numerous industries. That said, I think it would be an understatement for me to say that I am excited to finally share my completed investment thesis with the Spartan Community.

For those of you that are new to Spartan Trading, or are just receiving our free weekly newsletter for the first time, my goal is to cover one company in detail every quarter that I feel has good investment potential when considering risk / reward.

And those that are familiar with Spartan Trading know that I like to find early movers within the Biotech space. Not only do I think I have found a company that is an early mover, I think that I have found a company that could be revolutionary in providing solutions for age-related diseases, provided they are successful in completing their clinical trials.

For centuries humans have been searching for the “Fountain of Youth” in an effort to transcend aging; with multiple cultures claiming that youth will be restored to anyone who drinks from or bathes in it, symbolizing humanities desire for eternal youth and immortality.

There may be no evidence that such a “Fountain” exists – but what if there was a drug that could give people the chance to turn back their bodies biological age? What if we could reverse or mitigate age related diseases? What if we could repair damaged organs or other tissues?

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a preclinical stage pharmaceutical company with a groundbreaking focus on telomere regeneration and age-related inflammatory diseases. Its lead drug candidate, Telomir-1, presents a novel approach to extending telomeres, potentially reversing aging processes and addressing age related conditions such as osteoarthritis.

Backed by a strong management team, strategic partnerships, exclusive licensing agreements and promising pre-clinical results, this comprehensive investment thesis will explore why I feel that $TELO stands at the forefront of a transformative biotech opportunity and why an early investment could yield high returns, especially as they progress through clinical trials and into market adoption.

Spartan’s Technical Analysis

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO

  • Idea: Long $TELO $6.00 – $7.50 (Starter Position)
  • 1st Target Area: $9.41
  • 2nd Target Area: $11.27
  • 3rd Target Area: $15.55
  • Stops: $4.40

  • Float: 16.5M
  • Shares Outstanding: ~29.61M
  • Insider & Institutional Ownership: ~42.64%
  • Strategic Investors & Management Ownership: ~15M
  • Free Trading: ~1M (excluding strategic investors & management*)
  • Market Cap: 178.2M

  • Cash on hand: $1.23M
  • Debt: No Debt Outstanding
  • Burn Rate: $3.9M / Year

Back into the middle of its range, looking to build a position on the long side here, once that 50ema breaks to the upside will be looking for full size and continuation to the recent range. IMO this will be a faster position as it gets traction given the low float and the speculative news around the name. Low floats have also been quite hot as of late.

INVESTMENT THESIS

Background

Founded in 2021, Telomir Pharmaceuticals, Inc. (Telomir) is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions. Telomir’s goal is to develop and commercialize Telomir-1 (which is proposed to be dosed orally) for hemochromatosis (iron overload) and ultimately post-chemotherapy recovery and a broader range of other age-related inflammatory conditions such as osteoarthritis.

$TELO presents a compelling investment opportunity driven by its innovative technology, large market potential, strategic partnerships, and experienced management team.

As the company progresses towards key milestones, including preclinical data readouts and potential regulatory advancements, investor sentiment is likely to improve, reflecting positively on the stock’s valuation. With no direct competitors in the space and a clear path to address unmet medical needs, Telomir is positioned for long-term success in the burgeoning field of age-related therapeutics.

What are Telomeres?

Telomeres are structures made from DNA sequences and proteins found at the ends of chromosomes (TTAGGG). During cell division, telomeres allow cells to divide without losing genes by protecting the chromosome ends from becoming damaged, similar to a plastic cap on the end of a shoelace.

As humans age, telomeres progressively shorten with each cell division until cells eventually reach a critical length where they can no longer divide (Hayflick’s phenomenon). This state of irreversible growth arrest is known as cellular senescence (death) and is associated with aging and age-related diseases.

Metal reactivity (a build up of ionized metals in our system) can accelerate the telomere shortening process. There are also a number of other factors that can lead to accelerated telomere shortening:1

  • Stress
  • Regularly eating sugar laden / processed food
  • Extreme physical activity
  • Frequent smoking / vaping
  • Frequent lack of sleep / short sleep times
Groundbreaking Oral Stem Cell Therapy – Telomir-1

$TELO Telomir-1’s novel mechanism of action involves the elongation and stimulation of telomeres, crucial components in cellular aging. By inhibiting metals associated with age-related inflammatory conditions and disrupting specific inflammatory pathways, Telomir-1 shows promise in potentially reversing aging processes.

Telomir-1 offers a non-toxic oral therapeutic treatment, providing a convenient and patient-friendly alternative to existing therapies. Its extrusion through urine minimizes liver processing, enhancing safety and tolerability. 

Artificial Intelligence (AI) Modeling of Telomir-1

$TELO collaborated with InSilicoTrials, an innovator in leveraging AI and simulations to enhance drug development, to perform advanced AI modeling on Telomir-1. Early research has confirmed the mechanism of action of Telomir-1 and suggests that it may be a potent metal inhibitor, potentially leading to a reversal of aging through telomere regulation

Promising Preclinical Studies

Early preclinical studies and collaborations with InSilicoTrials indicate Telomir-1’s potential efficacy in telomere elongation and age reversal. Positive outcomes in animal studies, including improvements in mobility and cognitive functions, set the stage for significant milestones.

Mouse trials have shown a 10-fold increase in telomere counts within 10 days of treatment, restoring mobility and cognitive function.

Telomir-1 Mouse Dosing (Day 1) - Arthritic limb, difficulty walking, low activity / energy
Telomir-1 Mouse Dosing (Day 1) - Arthritic limb, difficulty walking, low activity / energy
Telomir-1 Mouse Dosing (Day 10) - Increased activity / energy, perceived absence of arthritic limb
Telomir-1 Mouse Dosing (Day 10) - Increased activity / energy, perceived absence of arthritic limb

See bottom of thesis for recent video interview with Frank O’Donnell, MD (Co-Founder & Special Advisor) explaining mouse trial results, demonstrating the effectiveness of Telomir-1 – Timestamp 04:35

Charles River Laboratories – Rat Study
Purpose: Determine the effects of Telomir-1 in the Monosodium-Iodoacetate (MIA) induced Osteoarthritis (OA) Joint Pain Model in the Aged Rat – Full study data delivery expected June 14, 2024.

High Level Overview:
  • Adult Sprague Dawley rats at 7-9 months old  used for the study.
  • Osteoarthritis induced by intra-articular injection of MIA (Monoiodoacetate) in the knee joint on Day 0.
  • Dosing of Telomir-1 by oral gavage performed from Day 3 to Day 14.
  • Dynamic Weight Bearing (DWB) will be assessed at different time points (Day 4, 7, 10 and 14) for evaluation of joint nociception.
Telomir-1 Canine Dosing (Pre Treatment) 12 Years Old - Advanced Cancer
Telomir-1 Canine Dosing (Pre Treatment) - 12 Years Old - Advanced Cancer
Telomir-1 Canine Dosing (After 1 Dose) - Healthier Coat, Energy Increase, Vitals Improved
Telomir-1 Canine Dosing (After 1 Dose) - Healthier Coat, Energy Increase, Vitals Improved

See bottom of thesis for recent video interview with Frank O’Donnell, MD (Co-Founder & Special Advisor) explaining the compassionate use case above, demonstrating the effectiveness of Telomir-1 in a large mammal (Canine) – Timestamp 07:25

Argenta – Midwest Veterinary Services, Inc – Canine Study

Purpose: Determining the efficacy of Telomir-1 on Mitigating the Clinical Signs of Osteoarthritis using a Femoral Induction Model in Laboratory Dogs. Start of in-life phase Q2 2024  End of Live Phase (necropsy) Q4 2024

Primary Objective: Evaluate the efficacy of Telomir-1 for mitigating the progression of osteoarthritis based on symptomatic, radiographic, gross pathologic and histopathologic evaluations of age reversal.

Secondary Objective: Demonstrate the safety of Telomir-1 when administered daily for 168 consecutive days.

Upcoming Milestones

$TELO Key milestones, such as the completion of the Rat and Canine studies, are expected to provide critical data on Telomir-1’s efficacy and safety profile, serving as catalysts for investor confidence and valuation growth. 

Positive results in the Canine Study could signal a successful transition to human trials. Intention is an initial IND filing in Q1 2025 for Osteoarthritis.

Market Opportunity – Large Addressable Market

According to Allied Market Research, the global longevity and anti-senescence therapy market was valued at $25.1 billion in 2020, and is projected to reach $44.2 billion by 2030, growing at a CAGR of 6.1% from 2021 to 2030.2

Telomir targets a substantial market opportunity, primarily focusing on osteoarthritis, the most common cause of disability in the world. With an estimated 528 million individuals globally affected by osteoarthritis3 and an increasing emphasis on anti-aging therapies, Telomir-1’s potential to address age-related inflammatory conditions broadens its market reach.

Current treatments for osteoarthritis provide symptomatic relief but fail to address the underlying causes.4 Telomir-1’s unique mechanism of action positions it to meet the unmet needs of patients seeking disease-modifying therapies.

The estimated value of the market is $7.4 billion worldwide in 2021, expected CAGR of 8.5% through 2030.5

If Telomir’s preclinical study results can be replicated in large clinical trials this technology may be able to combat an almost endless array of age-related diseases, leading to unimaginable market opportunities.

Strategic Collaborations & Intellectual Property (IP)

$TELO benefits from strategic collaborations with industry-leading and highly reputable organizations like John Hopkins School of Medicine, IQVIA, InSilicoTrials, and Charles River, enhancing its research capabilities and accelerating drug development. 

Exclusive licensing agreements ensure access to critical intellectual property rights, providing Telomir Pharmaceuticals with a competitive edge and long-term sustainability (and act as a potential attractor for acquisition interest from larger firms).

World Wide Patent Rights are licensed from an affiliated IP development company under a perpetual, worldwide exclusive license agreement that bears an 8% running royalty.

Experienced Management Team

Led by Co-Founder and CEO Chris Chapman, Telomir boasts an experienced management team with over 30 years of pharmaceutical industry expertise including Chief Medical Officer, inventor and Co-Founder, Dr. Frank O’Donnell, MD who holds over 40 US Patents.

The involvement of Dr. Michael F. Roizen, a prominent figure and New York Times Best Selling Author in the field of age-related medicine, lends credibility and strategic guidance to the company’s initiatives.

Potential Risks & Challenges

Despite the promising outlook, investing in preclinical stage biotech companies carries inherent risks, including regulatory hurdles, clinical trial failures, and intellectual property challenges. Moreover, the competitive landscape may evolve rapidly, necessitating continuous innovation and adaptation. Investors should carefully assess these risks and consider diversification strategies when investing in Telomir Pharmaceuticals.

Conclusion – Posed to Disrupt the Healthcare Landscape

$TELO represents a compelling investment opportunity at the forefront of biotechnological innovation where early investment could yield high returns, particularly as the company progresses through clinical trials and into market adoption..

With Telomir-1’s potential to address age-related inflammatory conditions and potentially reverse cellular aging, the company stands poised to disrupt the healthcare landscape significantly.

Backed by a robust management team, strategic collaborations, and promising preclinical study data, Telomir Pharmaceuticals is well-positioned to capture a substantial share of the burgeoning anti-aging and inflammatory disease markets. As the company progresses towards key milestones and regulatory advancements, investors can anticipate significant value creation and potential returns. However, prudent risk management and a long-term perspective are essential, given the inherent uncertainties associated with biopharmaceutical development.

By investing in $TELO investors may be able to not only participate in a transformative healthcare opportunity but also contribute to the advancement of longevity and improved quality of life for individuals worldwide.

Back into the middle of its range, looking to build a position on the long side here, once that 50ema breaks to the upside will be looking for full size and continuation to the recent range. IMO this will be a faster position as it gets traction given the low float and the speculative news around the name. Low floats have also been quite hot as of late.

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO

  • Idea: Long $TELO $6.00 – $7.50 (Starter Position)
  • 1st Target Area: $9.41
  • 2nd Target Area: $11.27
  • 3rd Target Area: $15.55
  • Stops: $4.40

Idea will be to hold for 6-12 months long as they complete the next few animal studies. If the Canine Study results are positive (and they show that they have either mitigated or reversed age-related diseases or health issues) IMO everyone in the world will be buying this drug for their pets.

This could potentially be a billion+ Revenue Catalyst on its own (without even having to go to human trials).

Current Idea is a Long on $TELO

More information on Telomir Pharmaceuticals, Inc, including their most recent press presentations and press releases can be found here.

 
Best Regards,
Spartan (aka ‘Chris’)
 

References:
1.  Roizen, M. Linneman, P. & Ratner, A (2002). The Great Age Reboot: Cracking the Longevity Code for a Younger Tomorrow. National Geographic.
2. https://www.alliedmarketresearch.com/longevity-and-anti-senescence-therapy-market-A14010
3. https://www.who.int/news-room/fact-sheets/detail/osteoarthritis
4. https://www.mayoclinic.org/diseases-conditions/osteoarthritis/diagnosis-treatment/drc-20351930
5. https://www.polarismarketresearch.com/industry-analysis/global-osteoarthritis-market

* Full Free Trading Float (including strategic investors & management) is ~5.387M

Stay up to date with Spartan’s Weekly Newsletter

This communication is for informational purposes only and should not be construed as an offer to buy or sell securities nor is it to be construed as personal investment advice. Nothing contained in this communication should be relied upon as a promise or representation as to future performance. An affiliate of Spartan Trading inc. (“Spartan”) has been engaged by Telomir Pharmaceuticals Inc (TP) to provide it with consulting, promotional and or marketing services, and the information contained in this communication has been prepared by or on behalf of TR. Spartan’s affiliate may receive compensation in the form of cash or securities from time to time for these services and may sell any such securities as permitted by law. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Neither the owner of Spartan nor any of its members, officers, directors, contractors or employees are licensed broker-dealers, account representatives, market makers, investment bankers, investment advisers, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed on Spartan Trading Inc related properties. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. Spartan makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Some of the content on this website contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which may be beyond a company’s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. It is hereby noted that forward-looking statements contained herein may include everything other than historical information, involve risk and uncertainties that may affect a company’s actual results of operation. A company’s actual performance could greatly differ from those described in any forward-looking statements or announcements mentioned on this website or the websites contained within. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company’s products; the company’s ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, a company’s past performance does not guarantee future results. Generally, the information regarding a company profiled or discussed on this website is provided from public sources www.spartantrading.com makes no representations, warranties, or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained through our website or in communications originating from our website. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and Spartan, nor its affiliates, has no obligation to update any of the information provided. Spartan, its owners, officers, directors, contractors and employees are not responsible for errors and omissions. From time to time certain content on this website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap or penny stock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled on this website may not have approved certain or any statements within the website. Spartan encourages viewers to supplement the information obtained from this website with independent research and other professional advice. The content on this website is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Third Party Web Sites and Other Information This website may provide hyperlinks to third party websites or access to third party content. Spartan, its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does Spartan control, endorse, or guarantee any content found in such sites. Spartan does not control, endorse, or guarantee content found in such sites. By accessing, viewing, or using the website or communications originating from the website, you agree that Spartan, its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that Spartan, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. Spartan uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the United States Securities and Exchange Commission (SEC). The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or the Financial Industry Regulatory Authority (FINRA) at: www.finra.org. In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/Investors/index.htm. Income Disclaimer Testimonials and examples used here are exceptional results which may not apply to the average purchaser. They are not intended to represent or guarantee that anyone will achieve the same or similar results through our service. The use of our information should be based on your own due diligence, and you agree that our company is not liable for any success or failure of your business that is directly or indirectly related to the use of our information. As with any business, your results may vary, and will be based on your individual capacity, business experience and expertise. There are no guarantees concerning the level of success you may experience. Income statements made by our customers are only estimates of what they have earned; there is no guarantee that you will make these levels of income. When using our information you accept the risk that these earnings and income statements differ by individual. There is no assurance that examples of past earnings can be duplicated in the future. There are unknown risks in business and on the internet that we cannot anticipate which can reduce results. We therefore cannot guarantee your future results or success and are not responsible for your actions. Spartan Trading Inc an affiliate of Spark Newswire Inc. has been retained by TP (NASDAQ:TELO) to perform consulting, promotional and or advertising services for a limited time with respect to the company we are profiling or discussing on this website and in exchange for such services has received cash compensation from TP. Questions regarding this website may be sent to info@spartantrading.com. Spark Newswire Inc and affiliate of Spartan Trading Inc. has a one month agreement with TP (NASDAQ:TELO) for the sum of one hundred and fifty thousand united states dollars. This agreement is for consulting and or marketing of TP (NASDAQ:TELO) which services include the issuance of this release and other opinions that we release concerning of TP (NASDAQ:TELO). Spartan Trading and affiliate Spark Newswire Inc has not investigated the background of TP (NASDAQ:TELO) the hiring party. Anyone viewing this newsletter should assume TP (NASDAQ:TELO) or affiliates of TP (NASDAQ:TELO) own shares of TP (NASDAQ:TELO) which they plan to liquidate, and further understand that the liquidation of those shares may or may not negatively impact the share price. Spartan Trading and affiliate Spark Newswire Inc has received this amount as a consulting and or production budget for advertising efforts and will retain amounts over and above the cost of production, copywriting services, mailing and other distribution expenses as a fee for our services. As such, our opinion is neither unbiased nor independent, and you should consider that when evaluating our statements of TP (NASDAQ:TELO).

Memorial Day Sale - Save up to 50%!

X